EUCRW (Eucrates Biomedical Acquisition) Marketable Securities: $0.00 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EUCRW Eucrates Biomedical Acquisition Corp EUCRW
22 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Eucrates Biomedical Acquisition Marketable Securities?

Eucrates Biomedical Acquisition EUCRW 22 Marketable Securities is $0.00 Mil as of Dec. 2022. GuruFocus rates EUCRW with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Eucrates Biomedical Acquisition's Marketable Securities for the quarter that ended in Dec. 2022 was $0.00 Mil.

Eucrates Biomedical Acquisition  (NAS:EUCRW) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Eucrates Biomedical Acquisition Marketable Securities Related Terms

Eucrates Biomedical Acquisition Marketable Securities Historical Data

* Premium members only.

The historical data trend for Eucrates Biomedical Acquisition's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eucrates Biomedical Acquisition Marketable Securities Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Marketable Securities
0.00 0.00 0.00

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EUCRW
22GF Score
Eucrates Biomedical Acquisition Corp EUCRW
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eucrates Biomedical Acquisition Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Eucrates Biomedical Acquisition (EUCRW) has a Marketable Securities of $0.00 Mil as of Dec. 2022. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Eucrates Biomedical Acquisition and its competitors.
Is Eucrates Biomedical Acquisition's Marketable Securities too high?
Eucrates Biomedical Acquisition's current Marketable Securities is $0.00 Mil. Overall, Eucrates Biomedical Acquisition has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Eucrates Biomedical Acquisition's Marketable Securities compare to FXCO and AEHA?
Eucrates Biomedical Acquisition's Marketable Securities of $0.00 Mil can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Diversified Financial Services company?
A good Marketable Securities depends on the Diversified Financial Services industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Eucrates Biomedical Acquisition and its competitors. Eucrates Biomedical Acquisition's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eucrates Biomedical Acquisition stock overvalued right now?
Eucrates Biomedical Acquisition (EUCRW) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Eucrates Biomedical Acquisition's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Eucrates Biomedical Acquisition (EUCRW), the current Marketable Securities is $0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eucrates Biomedical Acquisition Business Description

Address 250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Eucrates Biomedical Acquisition Corp is a blank check company.
22GF Score

Get the complete analysis for EUCRW

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price